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ABSTRACT
Although bilateral breast cancers are a rare condition in the general population, the incidence has increased sig-
nificantly in BRCA1 and BRCA2 gene carrier breast cancer patients. Besides the genetic susceptibility, many risk 
factors such as age, first breast cancer diagnosis age, lifestyle, and environmental factors may be effective in the 
development of this type of cancer. This study aimed to determine BRCA1/2 gene carriage in patients with bilateral 
breast cancer and to find out the risk factors that may lead to contralateral cancer formation. From 2016 to 2018, 
in Turkey, we grouped 31 women diagnosed with bilateral breast cancer synchronously and metasynchronously. 
Analysis of BRCA1 and BRCA2 genes of these women evaluated for clinical and pathological tumour character-
istics was performed using the NGS technique. No significant difference was found between the metachronous 
(MBBC) and synchronous (SBBC) groups in terms of clinical and pathological tumour characteristics. MBBC 
patients’ age at first diagnosis of breast cancer was lower than SBBC. Also, there was a statistically significant 
relationship between chronic diseases and MBBC cancers (c2 = 11.519; p = 0.001). In our study, disease-related 
variants were found only in three patients, and two of these variants were identified the first time in the literature. 
The risk of bilateral breast cancer of BRCA1/2 carriers increases when the first breast cancer is diagnosed at 
a young age and there is a significant family history of cancer. MBBC is associated with chronic diseases, and 
large-scale research will contribute to clarifying this relationship.
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Introduction
Breast cancer is the most common type of cancer in 
women all over the world and is one of the first causes 
of deaths due to female sex cancers [1]. Although this 
type of cancer is mostly seen in the unilateral breast, 
approximately 2% to 11% of all events are bilaterally 
detected, and the second most common malignancy in 
breast cancer patients is located in the contralateral 
breast [2]. The development of diagnostic, screening, 
and treatment techniques in cancer and increased 
survival of cancer patients are thought to lead to the 
more frequent observation of bilateral breast cancer. 
However, the causes of invasive or in situ histological 
types of lobular breast cancer, gene mutation, early 
detection of breast cancer, and a history of radiation 
exposure in previous cancer treatment are thought to 
increase the risk of BBC development [3, 4]. While the 
risk of BBC developmental cumulative incidence is 3.4% 
in 10 years in patients with unilateral breast cancer, this 
rate increases to 13–40% in women with BRCA mutation 
[5, 6]. BBC patients, according to the time elapsed be-
tween the detection of tumors in both breasts (although 
many authors have not yet reached a consensus), can be 
grouped as synchronous (SBBC) or meta-synchronous 
(MBBC) [7–10]. The number of studies investigating the 
clinical and pathological characteristics of both groups 
is not sufficient in the literature. In this study, we aimed 
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to evaluate the demographic and clinical characteristics, 
pathological details of tumours, and BRCA1/2 mutation 
status of patients we grouped as MBBC and SBBC.
Methods
We performed this study in 31 patients who were 
diagnosed with bilateral breast cancer and referred to 
the genetics department of Dr. Abdurrahman Yurtaslan 
Ankara Oncology Training and Research Hospital be-
tween June 2016 and January 2018 in order to clarify 
the genetic aetiology. All patients who participated in 
the study were in accordance with the National Com-
prehensive Cancer Network (NCCN) guidelines for 
BRCA1/BRCA2 test standards [11]. Of the patients’ 
demographic characteristics, background and family 
history, age at first and second cancer diagnosis, tu-
mour-node-metastasis (TNM) staging, oestrogen recep-
tor (ER)/progesterone receptor (PR), C-erbB-2 status, 
etc. were obtained from the patients themselves, their 
medical records, and the electronic database of the hos-
pital during genetic counseling. Bilateral breast cancer 
of patients was grouped into SBBC or MBBC based on 
the interval between the first and contralateral tumours 
(≤ 12 and > 12 months, respectively) [12]. All patients 
included in the study were informed about this study 
and gave written, informed consent for publication. The 
independent Ethics Committee of the Dr. Abdurrahman 
Yurtaslan Ankara Oncology Training and Research 
Hospital approved this descriptive case series study 
(Document No. 2020-02/536).
Genetic materials obtained from peripheral blood 
samples of patients were tested by next-generation 
sequencing methods to detect germline variants of 
BRCA1 and BRCA2 genes. In the genetic analysis of 
the patients, the Oncomine™ BRCA Research As-
say commercial kit was used, and this analysis was 
performed on the Ion S5™ System (Ion Torrent™) 
platform. In this analysis, all exonic regions and the 
part up to 20 base pairs of exon-intron boundaries 
were examined. The sequence results were compared 
with the human genome of hg19, and Ion Reporter 
Software Version 5.4 (Thermo Fisher Scientific) was 
used for bioinformatics analysis. The in silico analysis 
for the gene variants was performed using SIFT, Poly-
Phen2, DANN, PROVEAN, GERP, MPC, Mutation 
Assessor, Fathmm, and Mutation Taster. In this study, 
genomic changes were identified according to ACMG 
criteria [13].
SPSS (IBM SPSS Statistics 24) was used for all sta-
tistical calculations. Independent sample t-test (t-table 
value) and Mann-Whitney U test (Z-table value) sta-
tistics were used to compare the measurement values 
of two independent variables. c2 cross tables were used 
in the study of the relations of the two qualitative vari-
ables. A p-value less than or equal to 0.05 was considered 
statistically significant.
Results
Of the 31 patients who were treated and followed 
up for bilateral breast cancer between January 2016 and 
December 2017, 14 (45.16%) presented with SBBC and 
17 (54.84%) were diagnosed with MBBC, and all of them 
underwent BRCA1/2 genes analyses. The median age 
of all patients was 53 (range 39–73 years) years, SBBC 
patients were 49.5 (range 36–66) years old, and MBBC 
patients were 40 (range 1–61) years old. There was 
a statistically significant difference between breast can-
cers in terms of breast cancer diagnosis age (t = 2,276; 
p = 0.030). The time interval between cancers, breast 
CA first diagnosis age of metasynchronised patients 
was statistically significantly lower than synchronised 
patients (Tab. 1).  
In terms of the 31 bilateral breast cancer patients, 
patient demographics and tumour-related general fac-
tors are shown in Table 2. In the assessment of smoking 
status, women who smoked at least 10 cigarettes a day 
for 10 years or more were included in the positive group. 
Chronic diseases were recognised as conditions requir-
ing periodic monitoring and supportive care (hyperten-
sion, diabetes mellitus, goiter, familial Mediterranean 
Table 1. Age parameters of SBBC and MBBC groups
Synchronous (n = 14) Metasynchronous (n = 17) Statistical 
analysis* 
Probability
Variable     ± S.S. Median 
[Min–Max]
    ± S.S. Median 
[Min–Max]
Age (years) 52.93 ± 8.75 54.5 
[39.0–67.0]
54.29 ± 8.91 53.0 
[42.0–73.0]
t = –0.428
p = 0.672
Age at first ca dia. (years) 48.43 ± 8.83 49.5 
[36.0–66.0]
40.88 ± 9.47 40.0
[19.0–61.0]
T = 2.276
p = 0.030
Age at sec ca dia. (years) 48.64 ± 8.78 49.5
[36.0–66.0]
51.94 ± 8.61 49.0
[40.0–67.0]
t = –1.053
p = 0.301
*Independent Samples t-test (T-table value) statistics were used to compare the measurement values of two independent variables in the normal distribution data
X X
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Table 2. Baseline patient demographics and clinical details
Characteristic n (%) Characteristic n (%) Characteristic n (%)
Level of education
Elementary school 
High school
University
9 (29.0)
15 (48.4)
7 (22.6)
Age at first labour
Nulliparity
< 20
20–30
> 30
1 (3.2)
3 (9.7)
23 (74.2)
4 (12.9)
Mass size (left)
≤ 2 cm
2–4 cm
Multifocal
9 (49.9)
6 (33.4)
3 (16.7)
Working condition
Yes
No
7 (22.6)
24 (77.4)
First breast ca laterality
Left
Right
Bilateral
11 (35.6)
10 (32.2)
10 (32.2)
Mass size (right)
≤ 2 cm
2– ≤ 4 cm
> 4 cm
Multifocal
9 (45.0)
7 (35.0)
2 (10.0)
2 (10.0)
Residence
Rural
City
7 (22.6)
24 (77.4)
Time between cancers
Simultaneously
Simultaneously – ≤ 1 year
1 year – ≤ 5 years
5 years – ≤ 10 years
More than 10 years
10 (32.2)
4 (13.0)
3 (9.6)
3 (9.6)
11 (35.6)
Metastasis (at the 
first diagnosis)
None
Axillar
Bone
Lung
22 (71.0)
7 (22.6)
1 (3.2)
1 (3.2)
Smoking
Yes
No
7 (22.6)
24 (77.4)
BMI
Normal
Overweight
Obese
9 (29.0)
13 (42.0)
9 (29.0)
The first breast ca
diagnosis
Palpable mass
Swelling and disfigurement
Nipple discharge
Routine check
14 (41.1)
7 (20.6)
2 (5.9)
11 (32.4)
Metastasis (at 
the contralateral 
breast diagnosis)
None
Lung
Lung and bone
28 (90.4)
2 (6.5)
1 (3.1)
Menarche age
< 12
12–14
> 14
3 (9.7)
26 (83.8)
2 (6.5)
Menstrual periods
Regular
Irregular
28 (90.3)
3 (9.7)
The second breast ca diagnosis
Palpable mass
Swelling and disfigurement
Routine check
5 (15.6)
2 (6.2)
25 (78.2)
Histopathology (left)
Ductal carcinoma  
in situ
Invasive ductal 
carcinoma
Invasive lobular 
carcinoma
Mixed invasive 
carcinoma
Musinoz carcinoma
Metaplastic carcinoma
2 (7.1)
18 (64.3)
5 (17.8)
1 (3.6)
1 (3.6)
1 (3.6)
Relation between 
diagnosis and menopause
Pre-menopausal
After menopause
16 (51.6)
15 (48.4)
Breast feeding duration
No
≤ 1 year
1–2 years
More than 2 years
2 (6.5)
20 (64.5)
7 (22.5)
2 (6.5)
Number of relatives with 
cancer
1
2
3
4 and more
8 (44.4)
5 (27.8)
3 (16.7)
2 (11.1)
Histopathology 
(right)
Ductal carcinoma  
in situ
Lobular carcinoma 
in situ
Invasive ductal 
carcinoma
Invasive lobular 
carcinoma
Invasive apocrine 
carcinoma
1 (3.4)
1 (3.4)
20 (69.0)
6 (20.8)
1 (3.4)
Chronic disease/Surgical 
history
Yes
No
19 (61.3)/17 (54.8)
12 (38.7)/14 (45.2)
Relative with breast and over 
Ca
Breast
Over
17 (85)
3 (15)
 
fever, asthma, etc). Surgical history group; appendecto-
my, cholecystectomy, haemorrhoidectomy, etc. Patients 
undergoing surgeries were included. In the evaluation 
of cancer history in relatives, all cancers diagnosed in 
many organs such as breast, ovary, colon, and brain were 
included. Relatives diagnosed with breast and ovarian 
cancer were grouped separately. Metastasis status was 
determined in all patients after both the initial diagnosis 
and one-year follow-up. When calculating BMI (kg/m2), 
25.0–29.9 was considered as overweight, 30 and over as 
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obese, and 18.5–24.9 as healthy. While patients were 
mostly diagnosed with the first breast cancer because 
of a palpable mass complaint, the second breast cancer 
was diagnosed in many patients during their routine 
checks. The most common breast cancer histopathologi-
cal type of both breasts was invasive ductal carcinoma, 
and the mass size was ≤ 2 cm.
For BRCA1 and BRCA2 gene analysis, the ac-
cession numbers of these genes were accepted as 
NM_007294.3 (BRCA1) and NM_000059.3 (BRCA2), 
respectively. Genomic changes in BRCA1 and 
BRCA2 were detected in only nine (29%) of 31 patients 
(Tab. 3). Seven of these gene changes were in the 
BRCA2 (77.8%) gene, and two were in the BRCA1 (22.2) 
gene and were heterozygous contitions. Of these ge-
nomic changes, two were pathogenic, one was probably 
pathogenic, and the remaining seven were variants of 
uncertain significance (VUS).
In these genes, two variants which were not reported 
in the literature and classified as pathogenic by us 
were detected. The variants NM_007294.3 (BRCA1): 
c.2131_2132delAA (p.Lys711Valfs*6) in patient P28 and 
NM_000059.3 (BRCA2):c.1773_1776delTTAT (p.Ile-
591Metfs*22) in patient P13 were formed in the exonic 
regions of the genes. These variants caused a loss of 
function in the gene by means of the frameshift mu-
tation mechanism. Various insilico predictive analysis 
programs support that these variants have a deleteri-
ous effect on the gene or gene product. The variant 
c.8954-5a> G, detected in the BRCA2 gene of P14, 
was previously reported as a likely pathogenic variant 
in the literature [14, 15]. P13 and P14 patients were 
grouped as MBBC, and P28 patients were grouped as 
SBBC. These three patients had their first breast cancer 
diagnosis in their 40s and their cancer was first detected 
in the right breast. These patients had numerous can-
cerous relatives. Patients first consulted a doctor for 
a palpable mass in the right breast. After the analysis, 
these three patients were diagnosed with hereditary 
breast and ovarian cancer syndrome (HBOC) associ-
ated with BRCA1 and BRCA2 and were given genetic 
counseling. Because BRCA disease-related variants 
were seen in a small number of patients in our sample, 
it was not possible to compare them statistically with 
others in this group.
VUS variants were detected in BRCA1/2 genes of 
the remaining six patients, two of which were reported 
in the literature [16–19]. The variants detected in pa-
tients P2, P23, P24, and P26 had not been previously 
reported in the literature. Among the patients with 
VUS variant, P9 was remarkable because she was 
diag nosed as Hodgkin’s disease when she was 32 years 
old. In this patient, two separate VUSs were detected: 
NM_000059.3 (BRCA2):c.3310A > C (p.Thr1104Pro) and 
NM_000059.3 (BRCA2):c.3503T > A (p.Met1168Lys). 
The patient was 54 years old, was first diagnosed with 
MBBC in the left breast, and her family cancer history was 
not significant for HBOC. In patients with other VUSs, 
breast cancer was diagnosed almost exclusively in the left 
breast (except P24) and grouped as MBBC. In addition 
to giving genetic counseling to these patients, it was also 
planned to reevaluate all VUSs determined according to 
ACMG once every six months. In 10 (58.8%) patients with 
MBBC, the first cancer was detected in the left breast. The 
first application of patients in this group was usually due 
to a mass complaint addressed in the breast.
As a result of the comparison of demographic data of 
the patients grouped as SBBC and MBBC, a statistically 
significant relationship was found in the breast where 
the cancer was first localised (c2 = 18.850; p = 0.000). 
There was also a statistically significant relationship 
between the time interval of cancers and chronic disease 
(c2 = 11.519; p = 0.001) (Tab. 4). There was no signif-
icant relationship between the two groups in the other 
demographic data. In addition, histopathological data 
of tumors in both breasts were compared but no statis-
tically significant result was obtained in the groups. We 
performed a statistical analysis of the number of chil-
dren and the number of relatives with cancer variables 
by grouping according to the first diagnosis age of the 
patients as ≤ 40 years and > 40 years. The result was 
not statistically significant (p > 0.05).
Discussion
The NCCN guideline recommends the analysis of 
BRCA1 and BRCA2 genes in individuals with bilateral 
breast cancer [20]. In detecting multiple primer breast 
cancer of patients, the diagnostic criteria that Warren 
and Gates first determined in 1932 were used. These 
criteria include the following: that each tumour is ma-
lignant, it has its own pathological features and its own 
metastatic pathway and the diagnosis of metastatic or 
recurrent tumours can be excluded, and tumours occur 
in different parts or organs and are not continuous with 
each other [21].
In this study of BRCA1/2 gene analysis findings, 
demographic characteristics of 31 patients with bilateral 
breast cancer were investigated, and disease-causing 
gene variants were identified in three patients. In this 
way, the aetiology of the disease became clear in these 
patients. Of these gene variants, the frameshift ones 
were first described in our patient in the literature. These 
patients were diagnosed as HBOC and therefore were 
given genetic counseling. In addition, genetic counseling 
was given to six patients in whom the VUS variants were 
identified. VUS classification means that there is insuf-
ficient or conflicting evidence regarding a molecular 
alteration’s role in the disease, and hence a periodic 
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Table 4. Significant parameters of SBBC and MBBC groups
Variable SBBC (n = 14) MBBC (n = 17) Statistical 
analysis* 
Probability
n % n %
First Ca
Right
Left
Simultaneous
3
1
10
21.4
7.2
71.4
7
10
41.2
58.8
c2 = 18.850
p = 0.000
Chronic disease
No
Yes
10
4
71.4
28.6
2
15
11.8
88.2
c2 = 11.519
p = 0.001
*c2 cross tables were used to examine the relationships between the two qualitative variables
re-evaluation of the VUS identified in patients in the 
genetic test was planned.
Although there are many studies in the literature 
regarding the increase in breast cancer risk in individu-
als carrying BRCA1/2 gene mutations, there are fewer 
reports that determine this risk in contralateral breast 
cancer. In BRCA carriers, the risk of developing breast 
cancer until the age of 70 years is approximately 50–87%. 
These carriers have a 32–64% risk for the development 
of contralateral breast cancer. In the literature some au-
thors claim that the overall risk for contralateral MBBC 
is approximately 0.5%, and this risk may reach up to 3% 
of women with BRCA1/2 carriers, and even a 10-year 
risk of 13–40% can be reached [22, 23]. In another study, 
10-year contralateral breast cancer risk in BRCA1 car-
riers was reported to be 24%, and the same risk for 
BRCA2 carriers was 19% [6]. The unquestionable joint 
consequence obtained as a result of research in the lite-
rature is that BBC risk increases in carrier women with 
disease-related variants of the BRCA1/2 genes. Weitzel 
et al. searched women in detecting the first breast cancer 
diagnose age. And they determined that the diagnosis 
age of first cancer for BRCA1 and BRCA2 was on aver-
age 38.6 and 43.6 years old, respectively. In their study, 
they also examined the time interval between the two 
cancer diagnoses and found an average of 5.1 years for 
BRCA1 carriers and 5.2 years for BRCA2 carriers [24]. 
In another study, individuals with the BRCA1 mutation 
were shown to have a 1.6-fold risk of contralateral breast 
cancer compared to those with BRCA2 mutations [23]. 
Rogozińska-Szczepka et al. determined that the age 
at first diagnosis of bilateral cancer with BRCA car-
riers and BRCA non-carriers was at the age of 42 and 
49 years, respectively [25].
The importance of the first diagnosis age in breast 
cancer was emphasised in a study conducted by Met-
calfe et al., who found that ‘women diagnosed with 
breast cancer under the age of 40 had a 42% risk of 
developing contralateral breast cancer for 15 years 
and an annual risk of 2.8%. The same risk decreased 
to 19% in women who had their first diagnosis after 
50 years of age and the annual risk was 1.3%’ [6]. 
Graeser et al. conducted a similar study in relatives of 
BRCA1 mutation carriers and found that ‘those who 
received first diagnosis with breast cancer younger 
than 40 years of age had an increased 25-year con-
tralateral breast cancer risk compared to those older 
than 50 years (63% and 20%, respectively). The annual 
risk ratios were 2.5% in the young group and 0.8% in 
the other group’ [23].
In our study, we first examined 31 patients demo-
graphically. We then grouped all patients as SBBC and 
MBBC and compared them for tumour characteris-
tics. Fourteen of the patients (45.16%) were grouped as 
SBBC, and 17 (54.84%) were grouped as MBBC. The 
median age was 53 years for all patients, 49.5 years for 
SBBC patients, and 40 years for MBBC patients, and 
all values were the same as those in the literature [26]. 
32.4% of the patients were diagnosed with first breast 
cancer and 78.2% with second breast cancer during 
routine controls. For this reason, the fact that both 
healthy and breast cancer women are subject to routine 
checks plays an important role in the early diagnosis and 
determination of treatment options for this disease. In 
the literature, it has been illustrated that young patients 
are vulnerable to MBCC [7]. 
There was a statistically significant relationship 
between chronic disease and MBBC in our patient 
group (p = 0.001). The mean age of first and second 
cancer diagnosis in the MBCC group was 40 and 
49 years, respectively. The time interval between the 
two cancer diagnoses was 11 years (35.6) or more. It 
was found that 10 (71.4%) of the patients with SBBC 
had no chronic disease and 15 (88.2%) patients with 
MBBC had a chronic disease. Among these diseases, 
goitre, hypertension, diabetes mellitus, migraine, and 
some inflammatory diseases such as Behcet’s disease 
and familial Mediterranean fever can be considered. 
All these diseases require periodic monitoring, medi-
cal supportive care, and/or drug therapy. In order to 
investigate this relationship in more detail, it is impor-
tant to divide chronic diseases into subgroups in larger 
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patient groups and to question the relationship between 
the time of diagnosis of these subgroups and the dura-
tion of diagnosis of first and second breast cancer. In 
fact, chronic diseases diagnosed after the treatment of 
cancer, which is itself a kind of chronic disease, may be 
triggered by the long-term side effects of this treatment. 
Also, a chronic disease in the organism may provide 
a basis for facilitating the development of contralateral 
breast cancer due to itself and/or treatment. In the 
literature, a study showing an increased relationship 
of MBCC compared to SBBC in chronic diseases has 
not been published. The results of this study, which was 
carried out for the first time in a small group of patients 
in Turkey, should be confirmed in a large number of 
patient groups, and the underlying cause of this condi-
tion should be discovered.
In our patient groups, following the literature, 
there was a statistically significant difference between 
breast cancers in terms of breast cancer diagnosis age 
(p = 0.030). An aspect of the time interval between 
cancers was that the breast cancer first diagnosis age of 
MBBC patients was statistically lower than that of SBBC 
patients. A clear difference was not found between the 
tumour characteristics of both groups clinicopathologi-
cally [12].
Conclusion
Women with bilateral breast cancer who have 
a BRCA mutation carrier receive their first breast cancer 
diagnosis at an early age and have a remarkable fam-
ily history of cancer. MBBC patients receive their first 
diagnosis at an earlier age than those with SBBC. For 
the first time in the literature, this study demonstrated 
a significant association between MBBC with chronic 
diseases and SBCC. Increasing the number of patients 
and conducting larger-scale studies will help clarify 
the uncertainties in the relationship between chronic 
diseases and MBBC.
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